Application of CD47 in targeted therapy strategies for hematologic neoplasms
10.3760/cma.j.cn115356-20210708-00152
- VernacularTitle:CD47在血液肿瘤靶向治疗策略中的应用
- Author:
Yige SHEN
1
;
Weili ZHAO
Author Information
1. 上海血液学研究所 医学基因组学国家重点实验室 国家转化医学中心 上海交通大学医学院附属瑞金医院，上海 200025
- Keywords:
Hematologic neoplasms;
CD47-SIRPɑ;
CD47 monoclonal antibody;
CD47 bispecific antibody;
Targeted fusion protein
- From:
Journal of Leukemia & Lymphoma
2022;31(1):61-64
- CountryChina
- Language:Chinese
-
Abstract:
CD47 is widely expressed on the cell surface, and combines with signal regulatory protein α (SIRPα) to transmit the "don't eat me" signal, which plays a key role in self-recognition and tumor immune escape. Studies have shown that the high expression of CD47 in different hematologic neoplasms is associated with the occurrence, progression and poor prognosis of tumors. As a new immune checkpoint, CD47 is gradually becoming an effective target for tumor immunotherapy. and various related preclinical and clinical studies for hematologic neoplasms are underway. This article summarizes the application of CD47 in hematologic neoplasms, in order to provide references for the treatment.
